Ovarian cancer is considered the fifth leading cause of deaths amongst cancer cases in women. Although mesothelioma has historically affected more men than women, current mesothelioma patient demographics show that more women may now be at risk of mesothelioma.

Known for decades as an industrial disease, mesothelioma was associated with manufacturing labor, large refinery operations, shipbuilding and other such large-scale work arenas through much of the nineteen hundreds. These operations used asbestos either in process or as an additive for end products. Asbestos is a naturally occurring mineral that can be mined from the earth. Although it has been used heavily in product development and construction, and continues to be used worldwide, it is known to cause rare cancer mesothelioma.

Mesothelioma affects an estimated twenty thousand people annually around the world. Characterized by a long latency period, mesothelioma patients do not usually know they are developing the disease for twenty to fifty years after original asbestos exposure. Once asbestos fibers are inhaled they can begin a mutation in otherwise healthy tissues. Most commonly occurring in protective lung lining, malignant mesothelioma tumors grow in irregular patterns without demonstrating external symptoms.

Proper diagnosis of mesothelioma typically follows display of bronchitis or pneumonia like symptoms. These symptoms do not show up until mesothelioma’s more aggressive stage, after the long latency period. Mesothelioma treatments include surgery, chemotherapy and radiation therapy; these are considered palliative, as there is no cure for mesothelioma. Average life expectancy following diagnosis is eighteen months.

Deborah Rathjen, Chief Executive of Bionomics, said of the upcoming trials, “It has always been Bionomics’ intention to initiate further clinical trials of BNC105. The decision to undertake a clinical trial in women with ovarian cancer has followed extensive consultation with key opinion leaders in Australia and the US.”

Bionomics drug BNC105 would be a welcome addition to mesothelioma treatment options. Mesothelioma case numbers are on the rise worldwide, with as many as ninety thousand cased expected annually if asbestos use continues to go unchanged.

Mesothelioma is a respiratory cancer caused by asbestos, most often affecting lung-lining tissue. Characterized by a long latency period—often twenty to fifty years—mesothelioma patients are typically diagnosed later in life, well past a time when standard mesothelioma treatments have any curative effects.  Much like his choices for Father’s Day celebrations, Davis’s mesothelioma treatments have veered from the well-beaten path.

Although Davis is scheduled for his fifth mesothelioma surgery later this month, he has chosen a non-traditional approach to fighting cancer. Rather than the standard chemotherapies and radiation treatments prescribed, Davis has combated mesothelioma with vitamins, supplements and exercise to boost his immune system.

Davis recognizes the rarity of his health choices. He says, “I’m an enigma in a lot of ways. This thing (mesothelioma) is like going to a casino. To win, you have to be very lucky. It’s designed for you to lose. All you’re trying to do in the fight is make the odds a little more in your favor.

“The health care side of this has been a nightmare. There are too many doctors out there — some so-called authorities — who don’t really know what they’re doing, using treatments from the ’70s that just don’t work, copying someone else’s failures. I would have been dead long ago, if I had listened to some of the medical professionals and the treatments they suggested. I’ve learned the hard way that there are some pain medications, even some anesthetics, that (do) more harm than good.”

In preparation for the Triathlon this past weekend Davis took swimming lessons. “I was a runner. I’ve always run,” he said. “Swimming just isn’t my thing. I might be the only one in the race this weekend wearing water wings. I’ve become proof that a rock can swim. The triathlon has taken my mind off the surgery, and it has forced me to become healthier and physically stronger for the surgery.”

Davis has committed much of his time to raising awareness and funds for mesothelioma research. In the upcoming International Symposium on Malignant Mesothelioma, in Washington, D.C., June 23-25, Davis—and Linda Reinstein, founder of Asbestos Disease Awareness Organization—will receive the Volunteer of the Year Award.

This past weekend however, Davis and his daughter Courtney were focused on their triathlon goals and time together. Courtney said, “There is nowhere else I’d rather be on Father’s Day than with him in a triathlon. With this next surgery, we don’t know what’s around the corner for him, but he’s always been a fighter. And he’s not about to give up this fight anytime soon.”

Mesothelioma is a rare and aggressive cancer affecting the lining of lungs and other abdominal cavities. It grows in irregularly patterned tumors making it difficult to isolate and treat. Mesothelioma is also characterized by a long latency period, often between twenty and fifty years, in which the tumors develop, grow and spread, but cause no noticeable signs or symptoms. By the time symptoms demonstrate, the cancer is so far gone mesothelioma treatments only extends life expectancy and add to quality of life.

Mesothelioma is caused by exposure to asbestos, a toxic chemical used for decades in multiple industries in America and around the world. Today, building and equipment components contain countless components comprised of asbestos. As these materials break down and are destroyed with wear and damage, asbestos fibers are released into the air, threatening public health and safety.

Researchers conducted the study by closely examining over 300 case papers, specifically focusing on 9 incidents of mesothelioma. They concluded that PIT for mesothelioma patients might do more harm then good. In a report in Journal of Interactive and Cardiovascular Thoracic Surgery, they said, “One trial found that 23% of radiotherapy patients developed tract metastases compared to 10% of control patients… Time from procedure to tract metastases was in fact shorter in patients treated with RT (2.4 month RT vs. 6.4 months control). Another trial found that seeding of metastatic tumor to the intervention site occurred in 7% of RT sites vs. 10% of control sites.”

However, other papers have been written stating that no significant differences could be noted between mesothelioma patients who did or did not receive PIT using VATS. These reports encouraged providers to use PIT as an appropriate form of treatment for mesothelioma as long as consistent observation of the puncture wounds was included in follow-up care. One study actually showed there was a higher number of metastases occurrence in the control group than the group undergoing PIT. Other random studies have had varying results. Overall, metastases has not shown to limit life expectancy of mesothelioma patients.

Mesothelioma is a rare cancer of the abdominal cavity lining. Pleural mesothelioma is specific to mesothelioma of the lung lining, while peritoneal mesothelioma is that of other abdominal linings, such as the heart. Pleural mesothelioma is the more common of the two, affecting about three thousand Americans each year and an estimated ninety thousand worldwide.

Mesothelioma is caused by asbestos exposure. Asbestos fibers and dust can begin a mutative development if inhaled or ingested. Often taking twenty to fifty years to show signs and symptoms, mesothelioma grows irregularly patterned malignant tumors through the affected area. Many mesothelioma patients have no idea they were ever exposed to asbestos, making diagnosis difficult. Symptoms mimic those of pneumonia and bronchitis, so once patients do seek a physician’s counsel, proper diagnosis can be further postponed.

There is no known cure for mesothelioma. Many treatments are used to make patients as comfortable as possible and to extend life expectancy, which currently averages eighteen months following diagnosis. Mesothelioma treatments may include surgery, chemotherapy, radiation therapy and pain management.

Three hundred and ninety patients are expected to participate in the upcoming NGR-hTNF clinical trials. All patients have been diagnosed with malignant pleural mesothelioma and have undergone at least one round of treatment using the current standard pemetrexed-based chemotherapy. These new studies will focus on patients quality of life, survival times, progression-free times, and disease control in response to NGR-hTNF. Not only will the results of the clinical trials be a welcome addition in the medical community, but the studies will allow many mesothelioma patients to receive new, cutting edge treatments. Results are expected in 2013.

Mesothelioma is caused by exposure to asbestos fibers which can begin a cancerous development in abdominal cavity lining if inhaled. Characterized by a long latency period, often between twenty and fifty years, mesothelioma is difficult to diagnose. When symptoms do begin to show they mimic those of pneumonia and bronchitis further postponing proper diagnosis and treatment.

About three thousand Americans suffer with mesothelioma each year. Following diagnosis patient life expectancy ranges between six months and five years, averaging eighteen months. Many patients have no idea they were ever exposed to asbestos and therefore never think to consult a specialist about the possibilities of mesothelioma. There is no cure for this cancer; mesothelioma treatments include surgery, chemotherapy and radiation therapy.

Studies have already shown that garlic is beneficial against high blood pressure and high cholesterol and acts as an immune system support. Allicin, a chemical contained in garlic bulbs released when the bulb is cut, has both anti-bacterial and anti-fungal in properties. Research is proving that garlic’s allicin may also aid in cancer prevention.

Promising results were found in a study of allicin’s effects on cancer. Mice with cancer were injected with allicin and compared to those without the treatment. Mice given allicin lived up to six months past treatment, while those without the chemical lived only up to two months more.

Allicin has been proven to boost the immune system by inducing the body’s creation of more white blood cells. This is promising news as many cancer patients experiencing remission undergo immune system therapies to enhance what has been weakened by treatment and disease.

Twenty-eight out of thirty-seven studies showed that garlic intake is a good addition for overall health. Its cancer-direct merits continue to be tested, but with such claims already proving positive for high blood pressure, high cholesterol, immune support and cancer prevention, garlic may be quickly growing in favor.

Mesothelioma is an aggressive and terminal cancer caused by exposure to asbestos fibers. Asbestos fibers enter a patient’s body through inhalation or ingestion, and due to their microscopic size and odd needle like shape pass through the body’s normal defenses for collecting and expelling foreign debris. The fibers collect in the mesothelium, a protective soft tissue lining that encases the body’s organs, and causes severe tissue scarring. In time, scarring of the mesothelium can lead to the development of malignant tumors which spread and cause death, often in less than two years. Every year more than three thousand Americans are diagnosed with mesothelioma, and the rare cancer is becoming an even bigger problem worldwide as developing countries increase asbestos imports without effectively enforcing safe handling procedures.

Dr Joachim Aerts’ vaccine is particularly exciting because of its lack of serious side effects. If the treatment itself is sufficiently effective,it would considerably improve the quality of life of those patients whose current options are limited to harsh chemotherapy and radiotherapy. While conventional therapies induce such side effects as dramatic loss of strength, hair loss, weight loss, and weakening of the body’s autoimmune system, Aerts’ treatment at worst causes a brief stint of flu like symptoms.

The new treatment works with the patient’s dendritic cells to create the necessary antigins for combating the cancer. Dr Joachim, a lung specialist at Erasmus Medical Center in Rotterdam, Holland, hopes that his research will contribute to future treatments which enable a patient’s immune system to eradicate the disease. Immunotherapy techniques, if proven sufficiently effective in destroying cancer cells, will bring a great change to current cancer treatments and could vastly improve the prognosis of diseases like mesothelioma.

Some of the current limitations to immunotherapy are discussed in Dr. Aerts’ recently published study, including complications introduced by immunosuppressive disorders and some inherent difficulties in combating advanced tumors with autoimmune responses due to the state of the autoimmune system in patients with advanced cancers. Despite the obstacles, immunotherapy shows great promise for cancer treatment in the future.

The University of Hawaii’s Cancer Research Center’s designation as an NCI Cancer Center is important to mesothelioma research as it allocates financial and research support that helps scientists reach their goals of improving the disease’s diagnosis and treatment processes. Carbone had indicated that the NCI designation was in danger when he became the new director of the Cancer Center in September of 2009. Since then, the staff has worked to address the NCI’s specific concerns in an effort to maintain the assistance that improves the efficacy and output of their efforts.

The Hawaii Cancer Center has worked to fill many vacant positions, established partnerships and cooperative programs with other research facilities, and has begun the design of a new research center. These types of responsible developments could help them to maintain the NCI funding that’s vital to the mesothelioma research that they are conducting.

Mesothelioma affects more than 3,000 individuals annually in the United States alone, and brandishes a frightening prognosis that often gives patients no more than 18 months to live. The incurable cancer is caused almost exclusively by exposure to dangerous asbestos fibers, which through inhalation or ingestion can become lodged in a soft tissue called the mesothelium that protects our bodies’ vital organs. The disease can take decades to fully develop, and mesothelioma symptoms are so generic that they can be difficult to recognize properly.

Cancer Centers that are designated by the NCI are major contributors to the race for a cure for cancer. They are often recognized for their scientific excellence and their substantial discoveries in regards to improving the diagnosis and treatment of various cancers. While NCI supported Cancer Centers receive a huge amount of support that helps them to further their research, they must be re-evaluated each year to ensure that their research merits the NCI’s assistance.

The new drug, known as BCN105, will be tested this year on sixty different patients suffering from mesothelioma. The trials will aim to improve the prognosis for patients suffering from this aggressive form of cancer, as well as increase their quality of life.

Mesothelioma is an aggressive and fatal cancer that attacks the mesothelium, a soft tissue lining found in both the chest and abdominal cavities. Patients diagnosed with mesothelioma are normally given less than two years to live. The cancer has been linked with asbestos exposure and has become a source of controversy in regards to negligent practices on the part of industrial employers over the last century.

The new drug, BCN105, says Dr. Rathjen, is expected to be more effective against mesothelioma and other types of cancer due to the malignant cells’ inability to develop a resistance to its activities. In many chemotherapy treatments, cancerous cells eventually form an immunity to the drug being used and stop reacting to its presence after some time. In the past, this has necessitated the use of several different drugs being used during therapy to ensure that the cancer is unable to adapt. This practice, unfortunately, can contribute to a rapid deterioration of the patient’s health. Dr. Rathjen hopes that cancer cells will be unable to develop an immunity to BCN105 as effectively as existing treatments.

The Phase II trials will be conducted in Australia until the beginning of 2011. If the trials continue to show promise and can be proved effective against mesothelioma, Bionomics will begin to consider its commercial applications.

Mesothelioma affects between 2,000 and 3,000 people each year in the United States, comprising a substantial 3% of total cancer diagnoses in the country. The deadly cancer is caused by exposure to asbestos and asbestos fibers. It is a very aggressive, incurable cancer that occurs most commonly in the chest or abdominal cavities after the patient either inhales or ingests the dangerous substance. The disease can take several decades to occur after exposure to asbestos fibers, which contributes to the fact that it is exceedingly difficult to diagnose. Also contributing to the difficult diagnosis are the disease’s generic, flu like symptoms. Due to the aggressiveness of the cancer and the long amount of time it normally takes for a correct diagnosis, patients who learn that they have mesothelioma are often told they can expect to live only 6 to 18 months from their diagnosis. Mesothelioma’s very poor prognosis directly contributes to the value of supportive or palliative care options, which work to alleviate the patient’s discomfort and improve the time they have left to spend with their family and loved ones.

The Palliative Care Options conference will be conducted by a Dr. Charles F. von Gunten, an Associate Clinical Professor of Medicine at the Institute of Palliative Medicine in San Diego, California. Dr. von Gunten is among the nation’s leading experts in supportive care and aims to ensure that doctors, patients and families of patients are thoroughly informed about their options in when it comes to mesothelioma treatment. The doctor is the Editor in Chief of the Journal of Palliative Medicine, a renowned investigator of the National Cancer Institute, and the former President of the American Association for Cancer Education.

A thorough understanding of mesothelioma, likely treatment scenarios for the disease, and the role that supportive or palliative care can play can be incredibly important to both mesothelioma patients and their families alike. Often, an oncologist’s unrelenting determination to destroy or remove the cancer effectively can come at the cost of a reduced quality of life for the patient due to invasive and traumatic treatments. Palliative care aims to keep the patient’s best interests in mind in terms of both the quantity and the quality of their life. These options often promote treatments that will encourage a better overall experience for mesothelioma patients and their families. Depending on the circumstance, palliative care can be comprised of treatments like chemotherapy, radiotherapy, or surgeries to improve the patients ability to breath easily or to halt painful fluid buildup. Less intensive treatments such as meditation, dietary changes, acupuncture, massage and hypnosis may also be recommended to improve the patient’s comfort level.

During the conference next Tuesday, Dr. von Gunten will promote supportive care techniques to doctors, patients and their families that will improve the quality of their life and their overall treatment experience.

For seven years Dr. Malcolm Feigen, an Austin Health Centre Radiation Oncologist, has been researching and developing new mesothelioma treatment techniques which make use of high dose radiotherapy. So far, thirteen patients have been involved in the trial procedures. Dr. Feigan reports that advances in technology and available equipment have allowed the team at the Austin Health Centre to safely increase radiotherapy doses in their mesothelioma patients, and with impressive results.

“… we’ve been very impressed that in most cases there’s a considerable improvement in the activity of the tumour masses that we’ve given high doses of radiotherapy;” Dr. Feigan said, “and most patients have got through the course of treatment with no major side effects and some have had long-term benefits.”

The doctor continued to say that most patients treated exclusively with radiotherapy tend to realize short term benefits before the cancer becomes active again.

“But with radiotherapy it doesn’t come back in the same area and if we find patients early enough we may be able to stop any further developments of their disease,” he added.

Most of the patients involved in the trial treatment had surgery to remove cancerous tumors prior to radiotherapy, which seems to drastically improve the results. Dr. Feigan believes the new radiotherapy treatment in conjunction with other treatments shows plenty of promise, and on average can already give patients another two years to live.

“Some patients go on to have a number of good years before sometimes the tumour comes back in areas that we haven’t been able to give radiotherapy to,” he said.

“Some have had chemotherapy before they see us or afterwards and that does provide an additional benefit, but not always, and we think that most of the symptoms are relieved more effectively by high doses of radiotherapy than these other alternatives.”

A national oncology conference will receive Dr. Feigan next week to present his findings. The doctor hopes to gain some support for his research and encourage other cancer centres to help further his work.

The new treatment has already created somewhat of a stir which has been received by the medical community excitedly, if with some reservation. Professor Ian Olver, the CEO of the Cancer Council of Australia, welcomes further research in this direction and says that the findings to date are promising.

“I think it’s an important finding that radiation has a useful role along with other therapies, not so much on its own, so they’ve really found the niche for radiotherapy in this disease,” Professor Ian Olver said.